First Trust Advisors LP Vir Biotechnology, Inc. Transaction History

First Trust Advisors LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$23.2 - $27.29 $2.52 Million - $2.96 Million	-108,588 Reduced 44.95%	132,962 $3.26 Million
Q1 2023 May 15, 2023	SELL	$22.26 - $30.85 $465,278 - $644,826	-20,902 Reduced 7.96%	241,550 $5.62 Million
Q4 2022 Feb 09, 2023	BUY	$19.96 - $28.22 $2.3 Million - $3.26 Million	115,459 Added 78.55%	262,452 $6.64 Million
Q3 2022 Nov 14, 2022	BUY	$18.26 - $31.1 $2.3 Million - $3.91 Million	125,819 Added 594.21%	146,993 $2.83 Million
Q2 2022 Aug 12, 2022	SELL	$19.08 - $26.7 $1.17 Million - $1.64 Million	-61,536 Reduced 74.4%	21,174 $539,000
Q1 2022 May 13, 2022	BUY	$21.19 - $40.01 $1.38 Million - $2.61 Million	65,152 Added 371.07%	82,710 $2.13 Million
Q4 2021 Feb 08, 2022	SELL	$30.97 - $54.03 $1.02 Million - $1.77 Million	-32,814 Reduced 65.14%	17,558 $735,000
Q3 2021 Nov 15, 2021	SELL	$34.9 - $54.54 $1.58 Million - $2.48 Million	-45,395 Reduced 47.4%	50,372 $2.19 Million
Q2 2021 Aug 16, 2021	BUY	$38.75 - $51.0 $3.71 Million - $4.88 Million	95,767 New	95,767 $4.53 Million

218

87M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $982M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.